Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EU-CERT-ICD

Financiado

Cerrado

Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Imp...

Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope An estimated 500.000 sudden cardiac deaths (SCD) occur each year in the European Union. Patients at risk for SCD may benefit from prophylactic treatment with an implantable cardioverter-defibrillator (ICD). ICD implantations have... ver más

30/09/2018

UMG

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 22 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-09-30 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

22 Participantes

UMG

0.00€ | Lider

KANTONSSPITAL BASEL

N.D. | Participante

SKANE LAN

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STRICT SN The first blood biomarker to accurately STratify mortali... 120K€ Cerrado

RTC-2015-3515-1 ADAS - CARACTERIZACIÓN AUTOMÁTICA DEL SUSTRATO ARRÍTMICO Y E... 175K€ Cerrado

USART Ultrasound guided cardiac arrythmia treatment 1M€ Cerrado

PROFID Implementation of personalised risk prediction and preventio... 23M€ Cerrado

SN-marker Secretoneurin SN the first blood biomarker to accurately... 71K€ Cerrado

EURO SHOCK Testing the value of a novel strategic approach and its cost... 6M€ Cerrado

Líder del proyecto

UNIVERSITAETSMEDIZIN GOETTINGEN GEORGAUGUSTU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto An estimated 500.000 sudden cardiac deaths (SCD) occur each year in the European Union. Patients at risk for SCD may benefit from prophylactic treatment with an implantable cardioverter-defibrillator (ICD). ICD implantations have dramatically increased in recent years leading to multi-billion Euros of costs with significant regional disparities across Europe. Information on risks, benefits and costs supporting current guideline recommendations may be outdated, and the influence of gender remains unclear. EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe) aims to generate contemporary clinical outcome data on ICD effectiveness in Europe. Clinical outcomes including all-cause mortality, appropriate and inappropriate ICD shocks, and quality of life (QoL) are assessed by: - a prospective study of patients undergoing indicated ICD treatment for primary SCD prevention, with a control group of patients not undergoing ICD treatment - a large European registry collecting available data on prophylactic ICD treatment - meta-analyses of available and emerging ICD outcome studies QoL-adjusted cost-effectiveness will be estimated from actual cost comparisons and Markov decision models with attention to sub-groups, regional, and sex comparisons. Outcomes in patients receiving ICDs for primary SCD prevention will be compared in sub-strata, and with patients fulfilling guideline criteria but not undergoing therapy as per prior decision of treating physicians. Sub-groups with particularly large or small benefit from ICD implantation will be identified using risk markers and clinical characteristics with specific emphasis on gender. EU-CERT-ICD is expected to provide important novel information to validate or challenge current guideline indications for primary prophylactic ICD treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores